Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Non-Hodgkin's Lymphoma - Is There Room to Emulate Rituxan's Success?
- NEW YORK -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. Stakeholder Opinions: Non-Hodgkin's Lymphoma - Is there room to emulate Rituxan's success? To order this report: www.reportlinker.com/p074966/2008/02/Stakeholder-Opinions- Non-Hodgkins-Lymphoma---Is-there-room-to-emulate-Rituxans-success.html Non-Hodgkin's lymphoma NHL is the most common...
- Research articles 2008-02-20
- FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
- SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) today announced that the U.S. Food and Drug Administration FDA granted accelerated approval for Avastin([R]) bevacizumab, in combination with paclitaxel chemotherapy, for the treatment of patients who have not received chemotherapy for their metastatic HER2-negative breast cancer. The approval is based on...
- Research articles 2008-02-22
- Drug doubles survival rate among kidney cancer patients: study
- CHICAGO AFP — Anticancer drug Avastin, used for treating lung and colon cancer, has led to the doubling of the survival rate of people affected by kidney cancer, according to a new study released Saturday. The study, which surveyed 649 patients worldwide, showed that those who received Avastin, also...
- Research articles 2007-06-03
- Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models According to Data Presented.
- M2 PRESSWIRE-17 April 2007-Headline Maker: Peregrine's Selective Anti-VEGF Antibodies are as Effective as AvastinR in Preclinical Cancer Models According to Data PresentedC1994-2007 M2 COMMUNICATIONS LTD RDATE:17042007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors...
- Research articles 2007-04-17
- Avastin's Use in Treatment of Metastatic Breast Cancer Expected to Increase Dramatically on Heels of FDA's Accelerated Approval, According to Study by GfK Market Measures
- Research suggests Avastin's market share will more than double in both first- and second-line therapy use in patients with HER2 negative metastatic breast cancer
- Research articles 2008-03-10
- Genentech Provides Update on "AVAiL" Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
- SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) today announced an update for the previously reported Roche-sponsored international Phase III clinical study AVAiL of Avastin([R]) bevacizumab in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer NSCLC. The update confirmed the clinically and statistically...
- Research articles 2008-04-21
- Briton sells World Cup tickets to buy cancer drug
- LONDON AFP — A young cancer sufferer has said he had been forced into selling his World Cup semi-final tickets to raise cash for his treatment. Pharmacy student Nicholas Keher, 23, from Formby, near Liverpool in northwest England, was diagnosed with bowel cancer in February. The drug Avastin,...
- Research articles 2006-06-22
- Medical Advances Brighten Outlook For NJ's Cancer Patients
- The number of cancer deaths in the U.S. has been declining for some 15 years, but only lately has the rate of decline begun to outpace U.S. population growth. Medical experts speculate that increased longevity of cancer patients is due to people smoking less and to their being diagnosed and...
- Research articles 2006-04-01
- Switzerland gives green light to new Roche cancer treatment
- BASEL, Switzerland AFP — The Swiss drug giant Roche said it had won approval in Switzerland for a new cancer drug Avastin and hoped to get the go-ahead in over 90 other countries, including the European Union, soon. "The Swiss health authority Swissmedic has approved Avastin for the treatment...
- Research articles 2004-12-20
- Colon Cancer Drug Nears Approval after 34-Year Crusade.
- By Alice Dembner, The Boston Globe Knight Ridder/Tribune Business News Feb. 26--The first drug to emerge from a Harvard surgeon's 34-year crusade for a new class of cancer treatments is expected to win approval within weeks from the Food and Drug Administration,...
- Research articles 2004-02-26
- Study Tests Two Targeted Therapies Against Advanced Breast Cancer.
- Byline: UCLA LOS ANGELES, June 16 AScribe Newswire -- A new, early phase study at UCLA's Jonsson Cancer Center for the first time pairs two molecularly targeted drugs as a one-two punch to fight metastatic breast cancer. The drugs attack only the cancer and...
- Research articles 2003-06-16
- Genentech sets off-label price of Avastin at $100K
- GENENTECH HAS established the price for the off-label use of its colorectal cancer drug Avastin at $100,000. What has critics up in arms is not only the cost but also the message it sends.
- Research articles 2006-04-01
- Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
- SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) announced today that the company resubmitted a supplemental Biologics License Application sBLA to the U.S. Food and Drug Administration FDA for Avastin([R]) bevacizumab, in combination with paclitaxel chemotherapy, for patients who have not received chemotherapy for their locally recurrent or metastatic breast...
- Research articles 2007-08-24
- Avastin results cast cloud over anticancer class. (News).(Brief Article)
- THE GLOOMY results of Phase III trials for Genentech Inc.'s cancer drug Avastin (bevacizumab, rhuMAb-VEGF) sent shock waves across the market for a new class of anticancer drugs last week. While analysts maintain earnings per share forecasts, targe THE GLOOMY results of Phase III...
- Research articles 2002-09-16
- Genentech's Avastin poised for BLA. (Life Sciences).(biologics license application)
- GENENTECH INC. reported positive Phase III trial data for its anti-angiogenic drug Avastin bevacizumab in colorectal cancer, positioning the company to file a biologics license application BLA later this year. GENENTECH INC. reported positive Phase III trial data for its anti-angiogenic...
- Research articles 2003-06-09
- Genentech's Profit Up 48 Pct. on Backs of Cancer Patients; FTCR Calls for Fair Pricing of Drugs Developed with Taxpayer Grants
- SANTA MONICA, Calif., April 11 /U.S. Newswire/ -- Genentech posted a 48 percent profit increase today for the first quarter of 2006 following a recent announcement that the company would double the price of its cancer drug Avastin, to over $100,000 per yeSANTA MONICA, Calif., April 11 /U.S. Newswire/ --...
- Research articles 2006-04-11
- Genentech seeks early approval for oncology drug.(Life Sciences)
- GENENTECH INC. is seeking early approval for its newest oncology product Avastin bevacizumab with its filing of a completed biologics license application with the Food and Drug Administration FDA last week. The company is requesting priority re GENENTECH INC. is seeking early approval for...
- Research articles 2003-10-06
- Genentech Finds No Friends in Lucentis Pricing Flap
- Negative public opinion just keeps piling on to Genentech regarding its pricing policy on Lucentis and Avastin. This weekend saw a big Associated Press story describe how the company is refusing to ask the FDA to approve Avastin for use in treating "wet age-related macular degeneration," an eye condition that...
- Blog posts 2008-09-02
- As Roche Looks on, Genentech's Big Avastin Study Attracts Critics
- A handful of scientists are skeptical that Genentech’s C-08 trial of its Avastin anti-cancer drug will show any benefit in preventing the recurrence of colorectal cancer following surgery, reports PharmaWire via the Financial Times. Avastin is one of Genentech's most valuable products, and currently rakes in sales...
- Blog posts 2008-08-21
- Doctors vs. Drug Companies: Pharma is Winning -- So Far
- Earlier this week, the WSJ noted that oncologists are getting squeezed on the cost of expensive cancer drugs. Although the story features the usual anecdotes of doctors whose practices are in debt or who are shunting patients off to hospitals for treatment in order to save money, it’s still hard...
- Blog posts 2008-07-10
- << Previous
- page 1 of 2
- Next >>
Content Types
Refining Tags
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
